These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20217988)

  • 1. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
    Clayton RA; Gaston P; Howie CR
    J Bone Joint Surg Br; 2010 Mar; 92(3):468; author reply 468. PubMed ID: 20217988
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives. Epilogue.
    Merli G
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S33. PubMed ID: 21548181
    [No Abstract]   [Full Text] [Related]  

  • 4. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
    Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
    J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives.
    Merli G
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S4-5. PubMed ID: 21548183
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
    Kwong LM
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST; Scott LJ; Plosker GL
    Drugs; 2009; 69(13):1829-51. PubMed ID: 19719335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
    Ageno W
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):569-76. PubMed ID: 19505271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban for thromboprophylaxis after hip or knee replacement surgery.
    Belavic JM
    Nurse Pract; 2012 May; 37(5):6-8. PubMed ID: 22543875
    [No Abstract]   [Full Text] [Related]  

  • 11. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
    Cao YB; Zhang JD; Shen H; Jiang YY
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1099-108. PubMed ID: 20812009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data.
    Kwong LM
    Vasc Health Risk Manag; 2011; 7():461-6. PubMed ID: 21822393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.
    Friedman RJ; Sengupta N; Lees M
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):299-306. PubMed ID: 21671699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
    Cohen A; Drost P; Marchant N; Mitchell S; Orme M; Rublee D; Simon TA; Sutton A
    Clin Appl Thromb Hemost; 2012 Nov; 18(6):611-27. PubMed ID: 22387582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement.
    Turun S; Banghua L; Yuan Y; Zhenhui L; Ying N; Jin C
    Thromb Res; 2011 Jun; 127(6):525-34. PubMed ID: 21397931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New anticoagulants for the prevention of thromboembolism.
    Lepic K; Crowther M
    Curr Pharm Des; 2010; 16(31):3472-4. PubMed ID: 20858184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
    Eriksson BI; Kakkar AK; Turpie AG; Gent M; Bandel TJ; Homering M; Misselwitz F; Lassen MR
    J Bone Joint Surg Br; 2009 May; 91(5):636-44. PubMed ID: 19407299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban to prevent pulmonary embolism after hip or knee replacement.
    Cios D; Fanikos J
    Circulation; 2012 Apr; 125(14):e542-4. PubMed ID: 22492951
    [No Abstract]   [Full Text] [Related]  

  • 20. TB-402 for the prevention of venous thromboembolism in orthopaedic surgery: something new and promising, or not?
    Dentali F; Riva N
    Thromb Haemost; 2013 Jun; 109(6):977-9. PubMed ID: 23677042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.